Dresden relies on the molecular map

    

    

Doctors newspaper online, 19.10.2019

    

        
        
        

Thank you for your rating

        
    

    

     

    

• 

        

• 

        
        
    

    

MITS

DRESDEN. In Dresden, the foundation stone was laid at the end of September at the University Hospital Carl Gustav Carus for the new Center for Metabolic-Immunological Diseases and Therapy Technologies Saxony (MITS).

According to Uniangaben, from 2023 physicians, biologists, engineers and materials scientists are to work together in the new building in order to further develop a bioreactor and make it available to patients. This innovative capsule aims to cure diabetes and metabolic-immunological diseases.

Based on the only transplant center for insulin-producing cells in Germany, Dresden is the best location for this demanding project.

Eight million diabetics in Germany

Experts in the fields of internal medicine, endocrinology, immunology, surgery, transplantation medicine, cell biology and materials science developed new medical approaches to the diagnosis, treatment and prevention of metabolic diseases such as diabetes, in order to further expand their expertise. The federal government and the Free State are supporting the new construction costs, which amount to around 35.5 million euros, at an unspecified level.

In view of the more than eight million diabetics in Germany today, it is no longer enough to counter these and other common diseases with the prevention and therapy strategies known to date.

"In order to reduce the epidemic spread and develop new low-impact treatment approaches for patients, we have to leave the beaten path. One key to this is the intensive study of the molecular dimension of the metabolism, "explains MITS spokesman Professor Stefan R. Bornstein.

Observing Biochemical Processes

"Innovative diagnostic procedures help us with this – above all mass spectrometry and molecular imaging. In the future, they will allow us to observe biochemical processes of metabolism directly in a living organism, "he adds.

The MITS will be one of the institutions in Germany that develops and tests the necessary procedures. "The results will also make an important contribution to the further development of the bioreactor," says Bornstein confidently.

Professor Michael Albrecht, Medical Director of the Dresden University Hospital, sees the MITS as "an excellent example of the classical translational function of the university medical center Dresden." (maw)

• 

    

• 

    
    

        

More articles from this topic